Show simple item record

dc.contributor.authorGeldart, Tom
dc.contributor.authorIllidge, Timothy M
dc.date.accessioned2009-07-21T16:40:04Z
dc.date.available2009-07-21T16:40:04Z
dc.date.issued2005-08
dc.identifier.citationAnti-CD 40 monoclonal antibody. 2005, 46 (8):1105-13 Leuk. Lymphomaen
dc.identifier.issn1042-8194
dc.identifier.pmid16085550
dc.identifier.doi10.1080/10428190500085255
dc.identifier.urihttp://hdl.handle.net/10541/74818
dc.description.abstractNormal, bi-directional interactions between CD 40 and its natural ligand CD 154 (CD 40 ligand) are central to the generation of both T cell-dependent, humoral immune responses and cytotoxic T-cell responses. CD 40 is expressed on a broad range of hematological and epithelial malignancies. The development of monoclonal antibodies directed against CD 40 allows effective targeting of malignant cells through multiple mechanisms that include the recruitment of immune effector mechanisms such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, direct anti-proliferative effects on neoplastic cells and, importantly, by the activation of tumor-targeted cellular cytotoxicity. This review provides the background to the early clinical trial data that are now beginning to emerge for this potentially exciting new treatment approach.
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntigens, CD40
dc.subject.meshCD40 Ligand
dc.subject.meshHumans
dc.subject.meshImmunotherapy
dc.subject.meshLigands
dc.subject.meshModels, Immunological
dc.subject.meshNeoplasms
dc.subject.meshSignal Transduction
dc.titleAnti-CD 40 monoclonal antibody.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Oncology Unit, Cancer Sciences Division, School of Medicine, Southampton General Hospital, Southampton SO16 6YD, UK.en
dc.identifier.journalLeukemia & Lymphomaen
html.description.abstractNormal, bi-directional interactions between CD 40 and its natural ligand CD 154 (CD 40 ligand) are central to the generation of both T cell-dependent, humoral immune responses and cytotoxic T-cell responses. CD 40 is expressed on a broad range of hematological and epithelial malignancies. The development of monoclonal antibodies directed against CD 40 allows effective targeting of malignant cells through multiple mechanisms that include the recruitment of immune effector mechanisms such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, direct anti-proliferative effects on neoplastic cells and, importantly, by the activation of tumor-targeted cellular cytotoxicity. This review provides the background to the early clinical trial data that are now beginning to emerge for this potentially exciting new treatment approach.


This item appears in the following Collection(s)

Show simple item record